Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Dyslipidemia, Type 2 Diabetes

In brief

The goal of this clinical trial is to learn if drug CMG190303 to treat Type 2 Diabetes and Dyslipidemia in adults. It will also learn about the safety of CMG190303. The main questions it aims to answer are: -Primary Objectives: 1. To compare the change in HbA1c from baseline to 24 weeks between CMG190303 and Rosuvastatin 2. To compare the change in LDL-C from baseline to 24 weeks between CMG190303 and Dapagliflozin

Key facts

Study ID
NCT06772168
Run by
CMG Pharmaceutical Co. Ltd
People needed
240
Starts
2024-04-19
Expected to finish
2027-02-01
Last updated by the study team
2026-01-15

Who can join

Age: 19 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.